Abstract
AbstractImmunotherapy agents are now widely used in the treatment of metastatic melanoma. Immune‐related adverse events (irAEs) may occur, including cutaneous pathologies in 50% of patients. We report a case of Sweet syndrome (SS) in a patient who was prescribed ipilimumab and nivolumab for metastatic melanoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have